[Effects of 18ß-sodium glycyrrhetinic acid on TNF-α expression in rats with allergic rhinitis].

Objective:To observe the effect of 18ß-sodium glycyrrhetinic acid(18ß-SGA) on the expression of TNF-α in nasal mucosa of rats with allergic rhinitis（AR）, and explore the intervention mechanism of 18ß-SGA on AR. Method:One hundred and six SPF-level Wistar rats were randomly divided into control group, AR group, budesonide group, 18ß-SGA low dose group and high dose group. After the AR rat model was constructed by ovalbumin, the rats were given drug intervention and sacrificed after 2 and 4 weeks of intervention. The nasal mucosa of the rats was taken for immunohistochemical staining, RT-qPCR and Western-blotting to localize and quantify the expression of TNF-α. Result:By immunohistochemistry, Western-blotting and RT-PCR, TNF-α was mainly found in the columnar epithelium, vascular endothelium, glandular and some inflammatory cytoplasm of nasal mucosa. And the expression of TNF-α in the nasal mucosa of AR rats was significantly increased than the normal group at the protein and mRNA levels (P<0.01). After intervention with different doses of 18ß-SGA, the expression of TNF-α was significantly decreased (P<0.01), especially after 4 weeks of 18ß-SGA low dose group(P<0.01). Conclusion:Different doses of 18ß-SGA have therapeutic effects on AR, and its mechanism of action may be related to the inhibition of TNF-α expression.

[Effectiveness of P-Gemox chemotherapy combined with radiotherapy in newly diagnosed,stage â E to â ¡E, extranodal nasal type natural killer/T-cell lymphoma].

Objective: To investigate the efficacy and safety of pegaspargase, gemcitabine, and oxaliplatin(P-Gemox) chemotherapy combined with radiotherapy in the treatment of newly diagnosed, stage IE to IIE of Extranodal nasal type natural killer/T-cell lymphoma(ENKTL) patients.Method: P-Gemox chemotherapy combined with radiotherapy was used to analyze its clinical value and the factors affecting the prognosis in the treatment of 43 newly diagnosed ENKTL patients. In addition, toxicity related to chemotherapy was assessed. Result: The complete remission rate was 86.05% in 43 patients,the partial remission rate was 6.98%, and the total effective rate was 93.02%.Chi-square analysis showed tumor diameter, clinical stage and ECOG points were significant independent factors impacting on complete remission rate(P =0.025, 0.042, 0.037).The 1-year and 3-year overall survival rate and progression-free survival rate of 43 patients were 95.35% and 83.7%, 93.02% and 79.07%, respectively. Coxproportional analysis showed that tumor diameter and Ann Arbor stage were signifcant factors affecting overall survival(P =0.016,0.025).Adverse reactions caused by the P-Gemox chemotherapy regimen are mild and more common in grades I to II. Conclusion: The P-Gemox regimen combined with radiotherapy may be a promising option in the treatment of newly-diagnosed ENKTL due to its high efficacy yet low toxicity, and clinical stage has an important effect on CR and OS.

[Value of 18F-FDG PET/CT and PET in diagnosing and staging extranodal nasal type natural killer/T-cell lymphoma:A Meta-analysis].

Objective:The aim of this study is to comprehensively evaluate the values of 18F-FDG PET/CT and PET in diagnosing extranodal nasal type natural killer/T cell lymphoma (ENKTL). Method:Studies about ENKTL diagnosed by 18F-FDG PET/CT and PET until June 2018 were searched in the databases such as PubMed, Embase, Cochrane, Web of Science, CNKI, CBM, VIP and Wanfang. Two reviewers independently screened literature and extracted data strictly according to included and excluded criterion, and assessed bias risk by 11 items using QUADAS-2 gulidline. Meta-analysis was performed by Revmann 5.3 and Stata 12.0 software. The pooled weighted Sentivity (Sen), Specificity (Spe), Diagnostic odds ratio (DOR) were calculated,summary receiver operator curve (SROC) and area under SROC curve (AUC) were also drawn. Result:Ten studies with 457 patients and 5 092 foci on 18F-FDG PET/CT and 4 studies with 169 patients and 384 foci on PET were finally included in our Meta-analysis.Our research showed that pooled Sen, Spe, DOR and AUC of 18F-FDG PET/CT diagnosing ENKTL were 0.97 (95%CI 0.93-0.99), 0.97(95%CI 0.88-0.99), 1 131.07(95%CI 167.77-7 625.28), 0.99(95%CI 0.98-1.00), and they were 0.81 (95%CI 0.70-0.89), 0.90(95%CI 0.66-0.98), 39.63(95%CI 6.41-244.85), 0.86(95%CI 0.82-0.89), respectively. Z test result reveled that 18F-FDG PET/CT had better diagnostic value in detecting ENKTL compared to PET: AUC=0.99(95%CI 0.98-1.00) vs AUC=0.86(95%CI 0.82-0.89), Z=2.95, P=0.003. Conclusion:In comparasion with PET, 18F-FDG PET/CT had excellent diagnostic value in detecting and staging ENKTL and may served as a non-invasive imaging in diagnosing and staging ENKTL.

[Diagnostic value of magnetic resonance imaging for middle ear cholesteatoma: a Meta-analysis].

Objective:To evaluate the values of magnetic resonance (MR) in the diagnosis of middle ear cholesteatoma by meta-analysis. Method:The articles concerning the diagnosis of middle ear cholesteatoma by using MRI until September 2017 were searched in databases including The Cochrane Library, PubMed, CBM, VIP, Wan Fang Data and CNKI with the search term "cholesteatoma, MR, Magnetic Resonance". Two independent researchers screened literature, extracted data, and assessed the risk of the bias of included studies with the inclusion and exclusion criteria using the QUADAS-2 tool. Then, meta-analysis was performed using Stata 12.0 software. The pooled weighted sensitivity and specificity were calculated, the summary receiver operating characteristic curve (SROC) was drawn and the area under the curve was calculated. Result:A total of 21 original studies were included. The results of meta-analysis showed that the pooled sensitivity, specificity, DOR and area under SROC curve of MR for diagnosing middle ear cholesteatoma were 0.88 (95%CI0.83 to 0.92), 0.91 (95%CI0.86 to 0.95), 10.13 (95%CI6.20 to 15.55), 0.13 (95%CI0.09 to 0.19), 79.23 (95%CI37.74 to 166.33), and 0.96 (95%CI0.93 to 0.97), respectively. The 1.5T MR has little differences with 1.5T MR in diagnosing middle ear cholesteatoma. In contrast to retrospective studies, prospective studies have further demonstrated that MR has a higher diagnostic value for middle ear cholesteatoma. Based on regions, the analysis showed that MR in Europe was more valuable in the diagnosis of middle ear cholesteatoma. Conclusion:In the diagnosis of middle ear cholesteatoma, MR has a high value.